Takeda is serving as the Industry Lead in the newly launched INTERCEPT project to identify predictive biomarkers for Crohn's ...

Many with Crohn’s disease or ulcerative colitis sacrifice essential purchases like food and clothing for healthcare, survey ...

The INTERCEPT study is being funded to the tune of €38 million (nearly $40 million) over the next five years and is described ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that ... improve the early diagnosis and management of a wide range of debilitating ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Turmeric's active compound, curcumin, is a potent anti-inflammatory and antioxidant that can help with conditions like ...

Discover how wearable devices like Apple Watches and Fitbits can detect signs of IBD flares weeks before symptoms appear, ...

After battling with her own GI issues, Krystyna Houser took to innovating the Elemental Diet, a medical food which also ...

The IRA’s price controls discourage post-marketing research. The potential benefits from expanding access to the drug to ...

Research analysts at William Blair decreased their FY2025 earnings per share (EPS) estimates for shares of AbbVie in a note ...

For many individuals, the term “ostomy” may be unfamiliar, yet it represents a life-changing procedure that offers critical ...

William Blair reduced their FY2024 EPS estimates for shares of AbbVie in a research note issued on Tuesday, January 21st.